Pentoxifylline for the treatment of negative symptoms of Schizophrenia

Pentoxifylline as an adjuvant therapy in the treatment of negative symptoms of Schizophrenia: A randomized double blind and placebo controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N143

Enrollment

Registered

2022-05-26

Start date

2022-06-22

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: Patients (25 participants) treated with risperidone 4-6 mg per day + Pentoxifylline 400 mg twice a day for 8 weeks. Intervention 2: Control group: Patients (25 part

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Diagnosis of schizophrenia based on DSM-5 Age between 18-60 At least 2 years have been passed since the diagnosis Have been stable with risperidone treatment for at least 2 months 15 PANSS score for negative symptoms

Exclusion criteria

Exclusion criteria: Head trauma History of shock therapy during the last three months Neurosurgery Diagnosis of acute or chronic systemic disease History of drug allergy to risperidone or pentoxifylline Alcohol or drug addiction in the last 6 months Suicidal ideation Pregnancy or lactation IQ less than 70 based on the diagnosis of a psychiatrist.

Design outcomes

Primary

Measure	Time frame
Severity of schizophrenia. Timepoint: Baseline and weeks 4 and 8. Method of measurement: By Positive and Negative Syndrome Scale (PANSS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026